.Pharmacolibrary.Drugs.ATC.J.J06BB08 .Pharmacolibrary.Drugs.ATC.J.J06BB08| name: | StaphylococcusImmunoglobulin |
| ATC code: | J06BB08 | route: | intravenous |
| n-compartments | 1 |
Staphylococcus immunoglobulin is a human plasma-derived immunoglobulin G preparation enriched with antibodies to Staphylococcus aureus. It has been used for the prophylaxis and treatment of severe staphylococcal infections, especially in high-risk patients such as neonates, immunocompromised individuals, or those with extensive burns. It is not in widespread approved use in current clinical practice, with most immunoglobulins today being non-specific or targeted to other pathogens.
There are no published peer-reviewed sources providing detailed pharmacokinetic parameters for staphylococcus immunoglobulin in either healthy volunteers or patient populations. The following values are estimated based on typical human intravenous immunoglobulin (IVIG) pharmacokinetics.
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
François, B, et al., & Laterre, PF (2021). Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. The Lancet. Infectious diseases 21(9) 1313–1323. DOI:10.1016/S1473-3099(20)30995-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33894131
Weisman, LE, et al., & Mond, JJ (2009). Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. International immunopharmacology 9(5) 639–644. DOI:10.1016/j.intimp.2009.02.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19268719